Skip to main content

Advertisement

SpringerLink
Log in

Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Alemtuzumab is the treatment choice for patients with T-prolymphocytic leukemia (T-PLL). However, patients with T-PLL have a poor prognosis, and the option of allogeneic hematopoietic cell transplantation (HCT) remains controversial in these patients. This study aimed to analyze the outcomes of allogeneic HCT among patients with T-PLL to identify the potential clinical efficacy of allogeneic HCT. We retrospectively analyzed data from 20 patients with T-PLL, including five patients with complex chromosomal abnormalities at diagnosis who received an allogeneic HCT between 2000 and 2016. The median follow-up of survivors was 51 months in allogeneic HCT from human leukemia antigen (HLA)-matched donors. All five patients with complex chromosomal abnormalities died after allogeneic HCT. Our data suggest that allogeneic HCT from an HLA-matched donor can be considered for patients with T-PLL without complex chromosomal abnormalities. New treatment strategies of allogeneic HCT are required to improve the safety and efficacy of allografting in patients with T-PLL and complex chromosomal abnormalities. Potential approaches that identify patients with T-PLL and complex chromosomal abnormalities for allogeneic HCT with better disease control may allow identification of individuals who are suitable for allogeneic HCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

    Google Scholar 

  2. Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D (1998) Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 103:110–116

    Article  CAS  PubMed  Google Scholar 

  3. Hu Z, Medeiros LJ, Fang L, Sun Y, Tang Z, Tang G, Sun T, Quesada AE, Hu S, Wang SA, Pei L, Lu X (2017) Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol 92:441–447

    Article  CAS  PubMed  Google Scholar 

  4. Sud A, Dearden C (2017) T-cell Prolymphocytic Leukemia. Hematol Oncol Clin North Am 31:273–283

    Article  PubMed  Google Scholar 

  5. Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P (2019) EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Bone Marrow Transplant in press

  6. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, Kato K, Tabuchi K, Tsuchida M, Morishima Y, Mitamura M, Kawa K, Kato S, Nagamura T, Takanashi M, Kodera Y (2007) Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol 86:269–274

    Article  PubMed  Google Scholar 

  7. Atsuta Y (2016) Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3–10

    Article  PubMed  Google Scholar 

  8. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, Maziarz RT, Pulsipher M, McSweeney PA, Storb R (2008) Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992–2001

    Article  PubMed  Google Scholar 

  9. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reducedintensity conditioning regimen workshop: defining the dose spectrum-report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369

    Article  PubMed  PubMed Central  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828

    CAS  PubMed  Google Scholar 

  11. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956

    Article  Google Scholar 

  12. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458

    Article  CAS  Google Scholar 

  13. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM (2017) Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28:1554–1559

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M (2010) Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 16:543–547

    Article  PubMed  Google Scholar 

  15. Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P, EBMT Chronic Leukemia Working Party (2012) Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia 26:972–976

    Article  CAS  PubMed  Google Scholar 

  16. Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerm G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, François S, Peffault de Latour R, Yakoub-Agha I, Mohty M (2015) Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). Eur J Haematol 94:265–269

    Article  PubMed  Google Scholar 

  17. Dholaria BR, Ayala E, Sokol L, Nishihori T, Chavez JC, Hussaini M, Kumar A, Kharfan-Dabaja MA (2018) Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: a single-center experience. Leuk Res 67:1–5

    Article  PubMed  Google Scholar 

  18. Ali JM, Negus MC, Conlon TM, Harper IG, Qureshi MS, Motallebzadeh R, Willis R, Saeb-Parsy K, Bolton EM, Bradley JA, Pettigrew GJ (2016) Diversity of the CD4 T cell Alloresponse: the short and the long of it. Cell Rep 14:1232–1245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P (2017) GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplant 52:544–551

    Article  CAS  PubMed  Google Scholar 

  20. López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, Siebert R (2016) Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol 173:265–273

    Article  CAS  PubMed  Google Scholar 

  21. Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga Penas E, Vater I, Jayne S, Dyer MJ, Schrappe M, Dührsen U, Ammerpohl O, Russell RB, Küppers R, Dürig J, Siebert R (2014) Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 53:309–316

    Article  CAS  PubMed  Google Scholar 

  22. Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB (2017) First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood 130:2499–2503

    Article  CAS  PubMed  Google Scholar 

  23. He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, Mustjoki S, Aittokallio T (2018) Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients. Cancer Res 78:2407–2418

    Article  CAS  PubMed  Google Scholar 

  24. Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S (2018) Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia 32:774–787

    Article  CAS  PubMed  Google Scholar 

  25. Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M (2018) Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun 9:697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We appreciate the patients and clinical staff for their participation in the study. We are grateful to the Japanese Data Center for Hematopoietic Cell Transplantation for data management and the Clinical Research Institute of Kyushu Medical Hospital for their editorial support. We thank Ellen Knapp, PhD, from the Edanz Group (www.edanzediting.com) for editing a draft of this manuscript.

Funding

This study was supported by The Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED).

Author information

Authors and Affiliations

  1. Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, -8-1 Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan

    Satoshi Yamasaki

  2. Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Hideaki Nitta

  3. Department of Hematology, Kawasaki Medical School, Kurashiki, Japan

    Eisei Kondo

  4. Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida

  5. Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan

    Takuya Miyazaki

  6. Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan

    Ken Ishiyama

  7. Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan

    Miki Kiyota

  8. Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Kobe, Japan

    Hiroshi Matsuoka

  9. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Tatsuo Ichinohe

  10. Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Takahiro Fukuda

  11. Department of Healthcare Administration, Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta

  12. Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan

    Junji Suzumiya & Ritsuro Suzuki

Authors
  1. Satoshi Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideaki Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eisei Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoyuki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miki Kiyota
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tatsuo Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Junji Suzumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Yamasaki.

Ethics declarations

This study was approved by the data management committee of the Japanese Society for Hematopoietic Cell Transplantation and the Institutional Review Board of Kyushu Medical Center.

Informed consent

The Transplant Registry Unified Management Program database included physician-reviewed data. Observational studies based on the Transplant Registry Unified Management Program databases are performed with an informed consent.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamasaki, S., Nitta, H., Kondo, E. et al. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann Hematol 98, 2213–2220 (2019). https://doi.org/10.1007/s00277-019-03759-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03759-y

Keywords

Search

Navigation